Intermittent-fasting strategies yield small reductions in body weight compared with an ad libitum diet, according to a study.

Dapiglutide, a novel GLP-1/GLP-2 receptor agonist, was associated with body weight reductions of up to 8.3% at 13 weeks for ...

Muscle loss is common among those on GLP-1 receptor agonists — like semaglutide or liraglutide — which mimic gut hormones to ...